NANOG and glioblastoma: Overall, our finding suggested that HDACi resistance by IDH1R132H-induced NANOG, which attenuated by IDH1R132H inhibitor, AGI-5198, could be applied to improve therapeutic outcomes in glioblastoma patients with IDH1R132H mutation.